15 August 2023, Israel: Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), has announced the opening of a second site at The Davidoff Cancer Center for its ongoing Phase I clinical trial of its immuno-oncology drug candidate, BMC128. The trial aims to assess the safety and tolerability of BMC128 in combination with immune checkpoint inhibitor (ICI) immunotherapy, Bristol Myers Squibb’s Opdivo®, for the treatment of refractory patients with non-small cell lung cancer (NSCLC), melanoma, or renal cell carcinoma (RCC).
The Davidoff Center for the Treatment and Research of Cancer, situated at Beilinson Hospital, Rabin Medical Center (RMC), holds a preeminent position as Israel’s first and foremost comprehensive cancer center, known for its international leadership in cancer care. This state-of-the-art and patient-centric facility diligently serves over 200,000 patients annually, both from Israel and around the globe.
This new site at The Davidoff Center represents another milestone in Biomica’s commitment to advancing cutting-edge clinical research in immuno-oncology. The company established its first site at the Rambam Health Care Campus, where the first patient was dosed in July 2022 in the Phase I study of its Microbiome-Based immuno-oncology drug.
Prof. Gal Markel, Director of Davidoff Cancer Center and Biomica’s Scientific Advisory Board member, said: “I am excited about Biomica’s significant progress in their Phase I clinical trial at The Davidoff Cancer Center. As a Biomica Scientific Advisory Board member, I am proud to contribute my expertise to this important research endeavor. The exploration of microbiome-based immuno-oncology therapies represents a promising frontier in cancer treatment. I look forward to witnessing the potential impact of this approach on refractory patients with NSCLC, melanoma, or RCC.”
Dr. Elran Haber, CEO of Biomica, expressed his pride: “The opening of this new site at The Davidoff Center, a world-renowned cancer institution, marks an important milestone for Biomica’s BMC128 clinical program. Collaborating with esteemed Prof. Gal Markel further strengthens our commitment to advancing clinical research and expediting patient recruitment. We are resolute in our pursuit of accelerating progress and bringing hope to patients through innovative therapies.”
(For Latest Agriculture News & Updates, follow Krishak Jagat on Google News)